Compare COHR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHR | EW |
|---|---|---|
| Founded | 1971 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1B | 50.2B |
| IPO Year | 1995 | 1999 |
| Metric | COHR | EW |
|---|---|---|
| Price | $275.15 | $82.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $226.23 | $96.47 |
| AVG Volume (30 Days) | ★ 5.6M | 4.0M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.74 | N/A |
| EPS | ★ 1.95 | 1.83 |
| Revenue | $1,158,794,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | $21.62 | $13.39 |
| Revenue Next Year | $23.75 | $9.78 |
| P/E Ratio | $132.18 | ★ $45.27 |
| Revenue Growth | ★ 19.21 | 11.55 |
| 52 Week Low | $45.58 | $65.94 |
| 52 Week High | $300.20 | $87.89 |
| Indicator | COHR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 59.85 | 49.23 |
| Support Level | $170.95 | $80.91 |
| Resistance Level | $300.20 | $87.22 |
| Average True Range (ATR) | 21.08 | 2.22 |
| MACD | -1.23 | -0.21 |
| Stochastic Oscillator | 63.75 | 34.68 |
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.